{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:26:58Z","timestamp":1767677218749,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T00:00:00Z","timestamp":1581120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T00:00:00Z","timestamp":1581120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00404-020-05447-z","type":"journal-article","created":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T05:04:26Z","timestamp":1581138266000},"page":"779-785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic value of serum HE4 in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma"],"prefix":"10.1007","volume":"301","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5511-1179","authenticated-orcid":false,"given":"Dong","family":"Mi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuexiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,8]]},"reference":[{"key":"5447_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225\u2013249","journal-title":"CA Cancer J Clin"},{"key":"5447_CR2","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41467-017-01781-0","volume":"8","author":"R Mitra","year":"2017","unstructured":"Mitra R, Chen X, Greenawalt EJ, Maulik U, Jiang W, Zhao Z et al (2017) Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition. Nat Commun 8:1604","journal-title":"Nat Commun"},{"key":"5447_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71\u201396","journal-title":"CA Cancer J Clin"},{"key":"5447_CR4","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1200\/JCO.2008.18.1107","volume":"26","author":"K Levanon","year":"2008","unstructured":"Levanon K, Crum C, Drapkin R (2008) New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26:5284\u20135293","journal-title":"J Clin Oncol"},{"key":"5447_CR5","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1200\/JCO.2008.16.4814","volume":"26","author":"JW Carlson","year":"2008","unstructured":"Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y et al (2008) Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 26:4160\u20134165","journal-title":"J Clin Oncol"},{"key":"5447_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","volume":"31","author":"DW Kindelberger","year":"2007","unstructured":"Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F et al (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 31:161\u2013169","journal-title":"Am J Surg Pathol"},{"key":"5447_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/annonc\/mdt308","volume":"24","author":"L Dubeau","year":"2013","unstructured":"Dubeau L, Drapkin R (2013) Coming into focus: the nonovarian origins of ovarian cancer. Ann Oncol 24:28\u201335","journal-title":"Ann Oncol"},{"key":"5447_CR8","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1200\/JCO.2007.11.0932","volume":"25","author":"AN Fader","year":"2007","unstructured":"Fader AN, Rose PG (2007) Role of surgery in ovarian carcinoma. J Clin Oncol 25:2873\u20132883","journal-title":"J Clin Oncol"},{"key":"5447_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ejrad.2008.02.019","volume":"71","author":"P Gu","year":"2009","unstructured":"Gu P, Pan LL, Wu SQ, Sun L, Huang G (2009) CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 71:164\u2013174","journal-title":"Eur J Radiol"},{"key":"5447_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ygyno.2012.12.024","volume":"129","author":"T Levy","year":"2013","unstructured":"Levy T, Weiser R, Boaz M, Ben Shem E, Golan A, Menczer J (2013) The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients. Gynecol Oncol 129:165\u2013168","journal-title":"Gynecol Oncol"},{"key":"5447_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1245\/ASO.2003.05.015","volume":"10","author":"C Miralles","year":"2003","unstructured":"Miralles C, Orea M, Espana P, Provencio M, S\u00e1nchez A, Cantos B et al (2003) Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 10:150\u2013154","journal-title":"Ann Surg Oncol"},{"key":"5447_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","volume":"110","author":"LJ Havrilesky","year":"2008","unstructured":"Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q et al (2008) Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 110:374\u2013382","journal-title":"Gynecol Oncol"},{"key":"5447_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ygyno.2012.07.106","volume":"127","author":"MA Karlsen","year":"2012","unstructured":"Karlsen MA, Sandhu N, H\u00f8gdall C, Christensen IJ, Nedergaard L, Lundvall L et al (2012) Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol 127:379\u2013383","journal-title":"Gynecol Oncol"},{"key":"5447_CR14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/14737140.2017.1360138","volume":"17","author":"G Scaletta","year":"2017","unstructured":"Scaletta G, Plotti F, Luvero D, Capriglione S, Montera R, Miranda A et al (2017) The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. Expert Rev Anticancer Ther 17:827\u2013839","journal-title":"Expert Rev Anticancer Ther"},{"key":"5447_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ygyno.2017.07.130","volume":"147","author":"T Knific","year":"2017","unstructured":"Knific T, Osredkar J, Smrkolj \u0160, Tonin I, Vouk K, Blejec A et al (2017) Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer. Gynecol Oncol 147:126\u2013132","journal-title":"Gynecol Oncol"},{"key":"5447_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/14737159.2017.1282824","volume":"17","author":"W Qu","year":"2017","unstructured":"Qu W, Gao Q, Chen H, Tang Z, Zhu X, Jiang SW (2017) HE4-test of urine and body fluids for diagnosis of gynecologic cancer. Expert Rev Mol Diagn 17:239\u2013244","journal-title":"Expert Rev Mol Diagn"},{"key":"5447_CR17","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/jog.13053","volume":"42","author":"D Mi","year":"2016","unstructured":"Mi D, Zhang YX, Wang CJ, Feng Q, Qi P, Chen SQ (2016) Diagnostic and prognostic value of serum human epididymis protein 4 in patients with primary fallopian tube carcinoma. J Obstet Gynaecol Res 42:1326\u20131335","journal-title":"J Obstet Gynaecol Res"},{"key":"5447_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/1724600818796595","volume":"33","author":"D Mi","year":"2018","unstructured":"Mi D, Zhang Y (2018) Diagnostic and prognostic value of HE4 in female patients with primary peritoneal carcinoma. Int J Bio Markers 33:395\u2013400","journal-title":"Int J Bio Markers"},{"key":"5447_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T et al (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 11 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21:419\u2013423","journal-title":"Int J Gynecol Cancer"},{"key":"5447_CR20","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837\u2013845","journal-title":"Biometrics"},{"key":"5447_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ygyno.2016.01.016","volume":"141","author":"C Romagnolo","year":"2016","unstructured":"Romagnolo C, Leon AE, Fabricio AS, Taborelli M, Polesel J, Del Pup L et al (2016) HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: an Italian multicenter study. Gynecol Oncol 141:303\u2013311","journal-title":"Gynecol Oncol"},{"key":"5447_CR22","first-page":"382","volume":"33","author":"A Chudecka-G\u0142az","year":"2012","unstructured":"Chudecka-G\u0142az A, Rzepka-Go\u00b4rska I, Wojciechowska I (2012) Human epididymal protein 4 (HE4) is a novel biomarker and promising prognostic factor in ovarian cancer patients. Eur J Gynaecol Oncol 33:382\u2013390","journal-title":"Eur J Gynaecol Oncol"},{"key":"5447_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12032-017-1026-y","volume":"34","author":"S Capriglione","year":"2017","unstructured":"Capriglione S, Luvero D, Plotti F, Terranova C, Montera R, Scaletta G (2017) Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. Med Oncol 34:164","journal-title":"Med Oncol"},{"key":"5447_CR24","doi-asserted-by":"publisher","first-page":"12389","DOI":"10.1007\/s13277-014-2553-1","volume":"35","author":"T Vallius","year":"2014","unstructured":"Vallius T, Hynninen J, Auranen A, Carpen O, Matomaki J, Oksa S et al (2014) Serum HE4 and CA 125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. Tumor Biol 35:12389\u201312395","journal-title":"Tumor Biol"},{"key":"5447_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.clinbiochem.2018.08.003","volume":"60","author":"S Ferraro","year":"2018","unstructured":"Ferraro S, Robbiano C, Tosca N, Panzeri A, Paganoni AM, Panteghini M (2018) Serum human epididymis protein 4 vs carbohydrate antigen 125 in ovarian cancer follow-up. Clin biochem 60:84\u201390","journal-title":"Clin biochem"},{"key":"5447_CR26","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.3892\/or.2013.2682","volume":"30","author":"L Manganaro","year":"2013","unstructured":"Manganaro L, Michienzi S, Vinci V, Falzarano R, Saldari M, Granato T et al (2013) Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. Oncol Rep 30:2481\u20132487","journal-title":"Oncol Rep"},{"key":"5447_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ygyno.2012.09.003","volume":"127","author":"D Trudel","year":"2012","unstructured":"Trudel D, Tetu B, Gregoire J, Plante M, Renaud MC, Bacharov D et al (2012) Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecol Oncol 127:511\u2013515","journal-title":"Gynecol Oncol"},{"key":"5447_CR28","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1097\/IGC.0b013e3182681cfd","volume":"22","author":"KD Steffensen","year":"2012","unstructured":"Steffensen KD, Waldstrom M, Brandslund I, Petzold M, Jakobsen A (2012) The prognostic and predictive value of combined HE4 and CA 125 in ovarian cancer patients. Int J Gynecol Cancer 22:1474\u20131482","journal-title":"Int J Gynecol Cancer"},{"key":"5447_CR29","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1245\/s10434-013-3347-1","volume":"21","author":"EI Braicu","year":"2014","unstructured":"Braicu EI, Chekerov R, Richter R, Pop C, Nassir M, Loefgren H et al (2014) HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse. Ann Surg Oncol 21:955\u2013962","journal-title":"Ann Surg Oncol"},{"key":"5447_CR30","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.3892\/ol.2016.4533","volume":"11","author":"KD Steffensen","year":"2016","unstructured":"Steffensen KD, Waldstr\u00f8m M, Brandslund I, Lund B, S\u00f8rensen SM, Petzold M et al (2016) Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer. Oncol Lett 11:3967\u20133974","journal-title":"Oncol Lett"},{"key":"5447_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3892\/ol.2013.1339","volume":"6","author":"Z Yang","year":"2013","unstructured":"Yang Z, Luo Z, Zhang W, Zhang J, Li Z, Li L (2013) Diagnosis and preoperative value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer. Oncol Lett 6:28\u201334","journal-title":"Oncol Lett"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05447-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-020-05447-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05447-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T03:23:59Z","timestamp":1612841039000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-020-05447-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,8]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["5447"],"URL":"https:\/\/doi.org\/10.1007\/s00404-020-05447-z","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"type":"print","value":"0932-0067"},{"type":"electronic","value":"1432-0711"}],"subject":[],"published":{"date-parts":[[2020,2,8]]},"assertion":[{"value":"5 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"We declare that we have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}